Last $0.46 USD
Change Today -0.005 / -1.09%
Volume 42.8K
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

pressure biosciences inc (PBIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/14 - $0.78
52 Week Low
10/29/13 - $0.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

pressure biosciences inc (PBIO) Related Businessweek News

No Related Businessweek News Found

pressure biosciences inc (PBIO) Details

Pressure BioSciences, Inc. engages in the development of pressure cycling technology (PCT) in the United States. Its PCT technology uses instrumentation that cycles pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to control the interactions of bio-molecules. The company offers Barocycler instrumentation products comprising Barocycler NEP3229, which processes up to 3 samples using its single-use PULSE Tubes and up to 48 samples simultaneously through MicroTubes; Barocycler NEP2320 that processes 1 sample at a time and works on compressed air; Barocycler HUB440, a pressure generator for the laboratory bench; PCT MicroTube Adapter Kit, an ergonomically designed, space-saving Workstation; and The Shredder SG3, a shear mechanical homogenization system. It also offers consumable product line, which include The FT500 PULSE Tube that transmits the power of PCT from Barocycler instrument to the sample; The FT500-ND PULSE Tube, a plastic, single-use, and processing container with one chamber separated by a small disk with small holes; ProteoSolve for system biology, a PCT-dependent method for the extraction, isolation, and fractionation of nucleic acids, proteins, and lipids; ProteoSolve for Conventional Extraction, a PCT-dependent kit for the extraction of proteins; and Mitochondria Isolation Kits to extract mitochondria from skeletal muscle and lung tissue for subsequent analysis. Its PCT also has applications in various life sciences areas, such as genomic, proteomic, and small molecule sample preparation. It serves academic laboratories; government agencies; and biotechnology, pharmaceutical, and other life science companies. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in February 2005. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.

9 Employees
Last Reported Date: 03/31/14
Founded in 1978

pressure biosciences inc (PBIO) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $294.3K
Senior Vice President of Engineering
Total Annual Compensation: $197.6K
Vice President of Research and Development
Total Annual Compensation: $165.6K
Compensation as of Fiscal Year 2013.

pressure biosciences inc (PBIO) Key Developments

Pressure BioSciences, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Revenue Guidance for the Full Year of 2014

Pressure BioSciences, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. Total revenue for the fourth quarter of 2013 was $354,052 compared to $216,032 for the same period in 2012, a 64% increase. Operating loss for the fourth quarter of 2013 decreased to $900,110 from $1,129,750 for the same period in 2012, a reduction of 20%. Contributing to this decrease in operating loss was a quarter over quarter decrease in general and administrative expenses of $268,105, or 30%. Loss per common share (basic and diluted) was $0.16 for the 2013 fourth quarter compared to $0.10 for the same period in 2012. The additional loss per common share was due primarily to the change in the fair value of the derivative instruments in fourth quarter 2013. Loss before income taxes was $1,565,803 against $1,083,582 a year ago. Net loss applicable to common shareholders was $1,963,295 against $1,135,844 a year ago. Total revenue for the fiscal year 2013 was $1,503,288 compared to $1,238,217 for the fiscal year 2012, a 21% increase. Operating loss for the fiscal year 2013 decreased to $3,327,192 from $3,463,642 for the fiscal year 2012, a reduction of 4%. Contributing to this decrease in operating loss were decreases in total operating expenses of $22,792 and increased gross margin of $113,658. Loss per common share (basic and diluted) was $0.44 for 2013 compared to $0.43 for the same period in 2012. Loss before income taxes was $4,084,427 against $3,452,219 a year ago. Net loss applicable to common shareholders was $5,247,449 against $4,400,215 a year ago. The company believes that its product and services revenue will continue to increase in 2014 and beyond; that the distinct advantages of its pressure cycling-based products will continue to be reported by scientists worldwide; that the number of applications and thus fields of use for its products will continue to increase; and that it will be successful in continuing to raise the funds as required.

Pressure BioSciences, Inc., 2013 Earnings Call, Apr 01, 2014

Pressure BioSciences, Inc., 2013 Earnings Call, Apr 01, 2014

Pressure BioSciences Announces the Release and Initial Sale of the Barocycler HUB880

Pressure BioSciences, Inc. announced the commercial release of the Barocycler HUB880, the newest addition to the company's growing line of high-pressure instrument systems. The company also announced the sale (and shipment) of its first HUB880 system to Dr. Wayne Hubbell of the University of California Los Angeles (UCLA). PBI plans to showcase the HUB880 at the upcoming U.S. Human Proteome Organization's 10(th) Annual Conference to be held at the Westin-Seattle (WA), April 6-9, 2014. The Barocycler HUB880 is an automated, computer-controlled, bench-top, ultra-high pressure instrument. It was designed to have a safe and reproducible operating range from approximately 1,000 psi to approximately 100,000 psi (about 7,000 times normal atmospheric pressure). The company believes that these features will make the Barocycler HUB880 an instrument of choice for a broad range of studies that can utilize the special effects of ultra-high pressure on biological and other samples. The company believes that there are approximately 500,000 scientists worldwide working with biological samples, such as animal, plant, microbial, and human cells. These cells, and the biomolecules that constitute them (e.g., proteins, lipids, DNA) have historically been controlled (e.g., modified, inactivated, manipulated) using temperature and chemicals. However, studies have shown that cells/biomolecules also respond to specific levels of pressure in unique and reproducible ways. Thus, with its ability to reach ultra-high pressure levels significantly beyond any automated bench-top pressure instrument commercially available today, the company believes that the Barocycler HUB880 can potentially offer scientists the unique ability to control certain cells and biomolecules in ways never before achievable.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBIO:US $0.46 USD -0.005

PBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBIO.
View Industry Companies

Industry Analysis


Industry Average

Valuation PBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.6x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRESSURE BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at